Pall Corporation Reports Fourth Quarter and Full Year Results

Updated

Pall Corporation Reports Fourth Quarter and Full Year Results

PORT WASHINGTON, N.Y.--(BUSINESS WIRE)-- Pall Corporation (NYSE:PLL) today reported financial results for the fourth quarter and fiscal year ended July 31, 2013.

Fourth Quarter and Full Year Continuing Operations Sales and Earnings Overview(1)


Fourth quarter sales were $716.8 million compared to $722.4 million last year, a decrease of 1%. Sales in local currency ("LC") were up slightly. Diluted EPS were $0.76 in the quarter, compared to $0.64 last year. Pro forma diluted EPS(2) were $0.90, a 5% increase compared to $0.86 a year earlier, including a negative impact of approximately $0.03 from foreign currency translation.

For the full year, sales declined 1% over last year. Sales in LC increased 1%. Diluted EPS were $2.89 for the full year, compared to $2.39 for the same period last year. Pro forma diluted EPS(2) were $3.04, a 9% increase compared to $2.80 a year earlier, including a negative impact of approximately $0.10 from foreign currency translation.

Larry Kingsley, Pall President and CEO, said, "In light of continued economic challenges, particularly impacting our Industrial business, we delivered solid results this year. This was largely due to improved operational execution and the benefit of our structural cost actions."

Life Sciences - Fourth Quarter Highlights
(Dollar Amounts in Millions and Discussion of Sales Changes are in Local Currency)

Sales:

JUL. 31, 2013

JUL. 31, 2012

%
CHANGE

% CHANGE IN
LC

BioPharmaceuticals

$

215

$

205

5

6

Food & Beverage

47

50

(5

)

(4

)

Medical

54

51

5

5

Total Consumables

316

306

4

4

Systems

38

29

31

33

Total Life Sciences segment

$

354

$

335

6

6

Gross profit

$

201

$

194

% of sales

56.8

57.9

Segment profit

$

86

$

86

% of sales

24.2

25.7

BioPharmaceuticals: Consumables sales grew 6% compared to last year, on continued strength in the Biotech sector.

Food and Beverage: Consumables sales were down 4% compared to last year, on weakness in China as well as in several European countries.

Medical: Consumables sales grew 5% compared to last year, on strong sales in Hospital Critical Care and Blood Media.

Systems: Sales increased 33% compared to last year, on timing of BioPharmaceuticals and Food & Beverage capital spend.

Industrial - Fourth Quarter Highlights
(Dollar Amounts in Millions and Discussion of Sales Changes are in Local Currency)

Sales:

JUL. 31, 2013

JUL. 31, 2012

%
CHANGE

% CHANGE IN
LC

Process Technologies

$

151

$

151

(0

)

1

Aerospace

60

67

(11

)

(10

)

Microelectronics

73

83

(12

)

(7

)

Total Consumables

284

301

(6

)

(4

)

Systems

79

87

(9

)

(9

)

Total Industrial segment

$

363

$

388

(7

)

(5

)

Gross profit

$

168

$

179

% of sales

46.3

46.0

Segment profit

$

68

$

68

% of sales

18.8

17.4

Process Technologies: Consumables sales grew 1% compared to last year, on strength in Fuels & Chemicals.

Aerospace: Consumables sales were down 10% compared to last year, on weakness in Military Aerospace. This decline was largely due to strong helicopter program sales last year that did not repeat. Commercial Aerospace consumables sales grew 4%.

Microelectronics: Consumables sales were down 7% compared to last year, on continued weakness in the display and data storage end-markets.

Systems: Sales declined 9% compared to last year, on weakness in Municipal Water.

Conclusion/Outlook

Kingsley concluded, "In fiscal year 2014, we expect revenue growth in the low-to-mid single digits, resulting in pro forma EPS of $3.30 to $3.50, growth of 9% to 15%, representing significant operating leverage."

Conference Call

On Thursday, August 29, 2013, at 8:30 am ET, Pall Corporation will host a conference call to review these results. The call can be accessed at www.pall.com/investor. The webcast will be archived for 30 days.

About Pall Corporation

Pall Corporation (NYSE:PLL) is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The Company's engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation is an S&P 500 company serving customers worldwide. Pall has been named a "top green company" by Newsweek magazine. To see how Pall is helping enable a greener, safer, more sustainable future, follow us on Twitter @PallCorporation or visit www.pall.com/green.

Forward-Looking Statements

The matters discussed in this presentation contain "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Results for fiscal year 2013 are preliminary until the Company's Form 10-K is filed with the Securities and Exchange Commission on or before September 30, 2013. Forward-looking statements are those that address activities, events or developments that the Company or management intends, expects, projects, believes or anticipates will or may occur in the future. All statements regarding future performance, earnings projections, earnings guidance, management's expectations about its future cash needs, dilution from the disposition or future allocation of capital and effective tax rate, and other future events or developments are forward-looking statements.

Forward-looking statements are those that use terms such as "may," "will," "expect," "believe," "intend," "should," "could," "anticipate," "estimate," "forecast," "project," "plan," "predict," "potential," and similar expressions. Forward-looking statements contained in this and other written and oral reports are based on management's assumptions and assessments in light of past experience and trends, current conditions, expected future developments and other relevant factors.

The Company's forward-looking statements are subject to risks and uncertainties and are not guarantees of future performance, and actual results, developments and business decisions may differ materially from those envisaged by the Company's forward-looking statements. Such risks and uncertainties include, but are not limited to, those discussed in Part I-Item 1A.-Risk Factors in the 2012 Form 10-K, and other reports the Company files with the Securities and Exchange Commission, including: the impact of legislative, regulatory and political developments globally; the impact of the uncertain global economic environment; the extent to which adverse economic conditions may affect the Company's sales volume and results; demand for the Company's products and business relationships with key customers and suppliers, which may be impacted by their cash flow and payment practices; delays or cancellations in shipments; the Company's ability to develop and commercialize new technologies or obtain regulatory approval or market acceptance of new technologies; the Company's ability to enforce patents and protect proprietary products and manufacturing techniques; increase in costs of manufacturing and operating costs; the Company's ability to achieve and sustain the savings anticipated from its structural cost improvement initiatives; volatility in foreign currency exchange rates, interest rates and energy costs and other macroeconomic challenges currently affecting the Company; the Company's ability to meet its regulatory obligations; costs and outcome of pending or future claims or litigation; the Company's ability to comply with environmental, health and safety laws and regulations; changes in product mix, market mix and product pricing, particularly relating to the expansion of the systems business; the effect of a serious disruption in the Company's information systems; fluctuations in the Company's effective tax rate; the Company's ability to successfully complete or integrate any acquisitions; competition, including the impact of pricing and other actions by the Company's competitors; the effect of litigation and regulatory inquiries associated with the restatement of the Company's prior period financial statements; the Company's ability to attract and retain management talent or the loss of members of its senior management team; the effect of the restrictive covenants in the Company's debt facilities; and the effect of product defects and recalls. Factors or events that could cause the Company's actual results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company makes these statements as of the date of this disclosure and undertakes no obligation to update them, whether as a result of new information, future developments or otherwise.

Management uses certain non-GAAP measurements to assess the Company's current and future financial performance. The non-GAAP measurements do not replace the presentation of the Company's GAAP financial results. These measurements provide supplemental information to assist management in analyzing the Company's financial position and results of operations. The Company has chosen to provide this information to facilitate meaningful comparisons of past, present and future operating results and as a means to emphasize the results of ongoing operations.

Notes to Release:

(1)

As discussed in our news release dated August 1, 2012, the Company completed the sale of certain assets of its Blood product line. Accordingly, discussion of results from continuing operations excludes the Blood product line. Tables appended to this release are presented on a continuing operations basis (with reconciliation to include the discontinued Blood product line).

(2)

Pro forma diluted EPS are defined as Reported diluted EPS on a continuing operations basis adjusted for "Discrete Items." Discrete items are defined as Restructuring & Other Charges (ROTC) and other items that are deemed to be non-recurring in nature and/or not considered by management to be indicative of underlying operating performance. A reconciliation of Reported to Pro forma amounts can be found in the Reconciliation of Pro forma Earnings table accompanying this release.

(3)

Reflects assets held for sale related to the Blood product line.

(4)

Cash flows are inclusive of discontinued operations.

PALL CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(Amounts in Thousands)

JUL. 31, 2013

JUL. 31, 2012

Assets:

Cash and cash equivalents

$

936,886

$

500,274

Accounts receivable

566,335

655,436

Inventories

381,047

364,766

Other current assets

165,761

195,464

Assets held for sale

-

136,517

(3)

Total current assets

2,050,029

1,852,457

Property, plant and equipment

774,948

750,993

Other assets

647,862

744,442

Total assets

$

3,472,839

$

3,347,892

Liabilities and Stockholders' Equity:

Short-term debt

$

170,387

$

205,393

Accounts payable, income taxes and other current liabilities

558,684

646,735

Total current liabilities

729,071

852,128

Long-term debt, net of current portion

467,319

490,706

Deferred taxes and other non-current liabilities

461,493

495,023

Total liabilities

1,657,883

1,837,857

Stockholders' equity

1,814,956

1,510,035

Total liabilities and stockholders' equity

$

3,472,839

$

3,347,892

PALL CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS

(Unaudited)

(Amounts in Thousands, Except Per Share Data)

FOURTH QUARTER ENDED

YEAR ENDED

JUL. 31, 2013

JUL. 31, 2012

JUL. 31, 2013

JUL. 31, 2012

Net sales

$

716,818

$

722,371

$

2,648,063

$

2,671,656

Cost of sales

347,940

350,216

1,276,060

1,291,558

Gross profit

368,878

372,155

1,372,003

1,380,098

% of sales

51.5

%

51.5

%

51.8

%

51.7

%

Selling, general and administrative expenses

208,789

210,239

810,358

843,221

% of sales

29.1

%

29.1

%

30.6

%

31.6

%

Research and development

25,634

22,581

94,216

82,932

Operating profit

134,455

139,335

467,429

453,945

% of sales

18.8

%

19.3

%

17.7

%

17.0

%

Restructuring and other charges ("ROTC") (a)

18,685

35,857

40,182

66,858

Interest expense, net (c)

4,874

2,495

15,621

20,177

Earnings from continuing operations before income
taxes

110,896

100,983

411,626

366,910

Provision for income taxes (b)

24,689

25,272

81,664

85,963

Net earnings from continuing operations

$

86,207

$

75,711

$

329,962

$

280,947

Earnings/(loss) from discontinued operations, net of
income taxes

(579

)

Advertisement